These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31160496)

  • 1. Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy.
    Sultan AA; Muller S; Whittle R; Roddy E; Mallen C; Clarson L
    CMAJ; 2019 Jun; 191(22):E597-E603. PubMed ID: 31160496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of fragility fracture among patients with gout and the effect of urate-lowering therapy.
    Sultan AA; Whittle R; Muller S; Roddy E; Mallen CD; Bucknall M; Helliwell T; Hider S; Paskins Z
    CMAJ; 2018 May; 190(19):E581-E587. PubMed ID: 29759964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
    Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
    Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
    Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
    Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.
    Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M
    Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
    Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
    Int J Rheum Dis; 2022 Feb; 25(2):154-162. PubMed ID: 34796661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of allopurinol use on urate concentration and cardiovascular outcome.
    Wei L; Mackenzie IS; Chen Y; Struthers AD; MacDonald TM
    Br J Clin Pharmacol; 2011 Apr; 71(4):600-7. PubMed ID: 21395653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy.
    Drivelegka P; Sigurdardottir V; Svärd A; Jacobsson LTH; Dehlin M
    Arthritis Res Ther; 2018 Jun; 20(1):108. PubMed ID: 29855389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Gout in a Hospital Setting: A Lost Opportunity.
    Wright S; Chapman PT; Frampton C; O'Donnell JL; Raja R; Stamp LK
    J Rheumatol; 2017 Oct; 44(10):1493-1498. PubMed ID: 28765252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
    Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
    Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study.
    Kubota Y; McAdams-DeMarco M; Folsom AR
    Thromb Res; 2016 Aug; 144():144-8. PubMed ID: 27337701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
    Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
    Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
    Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study.
    Kok VC; Horng JT; Chang WS; Hong YF; Chang TH
    PLoS One; 2014; 9(6):e99102. PubMed ID: 24897240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
    Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
    PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
    Fang YJ; Chung YL; Lin CL; Lim YP
    Biomed Res Int; 2020; 2020():6358954. PubMed ID: 32775432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.